The Role of Adalimumab in Recurrent Pregnancy Loss Due Immune Dysregulation: A Case Series Report
- PMID: 40390909
- PMCID: PMC12085429
- DOI: 10.1007/s13224-024-02083-4
The Role of Adalimumab in Recurrent Pregnancy Loss Due Immune Dysregulation: A Case Series Report
Abstract
Tumor necrosis factor-alpha, a multifunctional T-helper 1 (Th1) cytokine, plays a significant role in placentation and embryonic development. Altered expression of TNF-α has been implicated in adverse pregnancy outcomes such as recurrent pregnancy loss (RPL) and pre-eclampsia (PE). The use of TNF-α inhibitors (TNFi) like Adalimumab (AD) has garnered attention for its ability to traverse the placental barrier, and modulating maternal immune responses during pregnancy. In this article, we have discussed two patients in whom the immunological factors have been identified in otherwise unexplained RPL and how the use of TNFi could be of help to achieve a viable pregnancy.
Keywords: Adalimumab; Autoimmune; Recurrent pregnancy loss (RPL); Tumor necrosis factor alpha blocker TNFi.
© Federation of Obstetric & Gynecological Societies of India 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Conflict of interest statement
Conflict of interestThe authors declare no conflict of interest.